ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,230.57
0.18%
Dow Jones
39,544.35
0.29%
US Dollar vs MXN
16.831
0.20%
Brent Oil
82.775
-0.52%
Bitcoin
61,454.33
-2.30%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Iovance Biotherapeutics Inc (IOVA)

  7. Iovance Biotherapeutics Inc (IOVA) Noticias

IOVA Iovance Biotherapeutics Inc

11.065
0.185 (1.70%)
Última actualización: 08:56:48
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Iovance Biotherapeutics Inc IOVA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.185 1.70% 11.065 08:56:48
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
10.92 10.80 11.18 10.88
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
09/5/202416:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202415:06EDGAR2Form 8-K - Current report
09/5/202415:01GLOBEIovance Biotherapeutics Reports First Quarter 2024 Financial..
01/5/202405:01GLOBEIovance Biotherapeutics to Host First Quarter 2024 Financial..
30/4/202405:01GLOBEIovance Biotherapeutics to Present at Upcoming Conferences
24/4/202415:01GLOBEIovance Biotherapeutics to Present Clinical and..
19/4/202416:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
22/3/202416:30GLOBEIovance Biotherapeutics Reports Inducement Grants under..
06/3/202417:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202407:00EDGAR2Form 8-K - Current report
04/3/202405:30GLOBEIovance Biotherapeutics Announces FDA has Lifted Clinical..
01/3/202416:00GLOBEIovance Biotherapeutics to Present at Upcoming Conferences
29/2/202406:30EDGAR2Form 8-K - Current report
28/2/202415:05EDGAR2Form 8-K - Current report
28/2/202415:01GLOBEIovance Biotherapeutics Reports Fourth Quarter and Full Year..
22/2/202415:53EDGAR2Form 8-K - Current report
22/2/202407:45GLOBEIovance Biotherapeutics to Host Fourth Quarter and Full-Year..
21/2/202415:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/2/202416:23EDGAR2Form 8-K - Current report
20/2/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202405:30GLOBEIovance Biotherapeutics, Inc. Announces Pricing of $211..
20/2/202405:03EDGAR2Form 8-K - Current report
16/2/202416:30GLOBEIovance Biotherapeutics Reports Inducement Grants under..
16/2/202414:38GLOBEIovance Biotherapeutics to Host Conference Call and Webcast..
16/2/202414:19GLOBEIovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA..
14/2/202405:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/1/202416:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
18/1/202417:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202417:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202417:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202416:03EDGAR2Form 8-K - Current report
28/12/202306:27IHMARKETNEWSWall Street Highlights: Amazon to Introduce Ads on Prime..
27/12/202316:00EDGAR2Form 8-K - Current report
27/12/202306:54DJNIovance Shares Fall Premarket As FDA Places Study On Hold..
27/12/202306:00GLOBEIovance Biotherapeutics Announces Clinical Program Update..
22/12/202316:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
17/11/202316:00GLOBEIovance Biotherapeutics Reports Inducement Grants under..
07/11/202316:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202315:05EDGAR2Form 8-K - Current report
07/11/202315:01GLOBEIovance Biotherapeutics Reports Third Quarter and..
31/10/202315:01GLOBEIovance Biotherapeutics to Host Third Quarter and..
31/10/202308:05GLOBEIovance Biotherapeutics to Present Clinical and Pre-Clinical..
20/10/202316:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
18/10/202319:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
IOVA
Iovance Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados